PSTV – plus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
Form 8-K PLUS THERAPEUTICS, INC. For: Nov 17
Form 4 PLUS THERAPEUTICS, INC. For: Nov 04 Filed by: Sims Andrew John Hugh MacIntyre
Form 10-Q PLUS THERAPEUTICS, INC. For: Sep 30
Form 8-K PLUS THERAPEUTICS, INC. For: Oct 30
Form 8-K PLUS THERAPEUTICS, INC. For: Oct 16
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.